Holen Sie sich die Stockscreener-App
0.8833
2.85%
0.0245
Handel nachbörslich:
.88
-0.0033
-0.37%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8588
Offen:
$0.8585
24-Stunden-Volumen:
1.61M
Relative Volume:
0.72
Marktkapitalisierung:
$167.19M
Einnahmen:
$154.90M
Nettoeinkommen (Verlust:
$-20.20M
KGV:
-7.3303
EPS:
-0.1205
Netto-Cashflow:
$-27.91M
1W Leistung:
+4.15%
1M Leistung:
-25.77%
6M Leistung:
-21.13%
1J Leistung:
-52.25%
1-Tages-Spanne:
$0.8415
$0.8896
1-Wochen-Bereich:
$0.8336
$0.8953
52-Wochen-Spanne:
$0.7362
$2.30
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.8833 | 162.55M | 154.90M | -20.20M | -27.91M | -0.1205 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
HRTX PE Ratio & Valuation, Is HRTX Overvalued - Intellectia AI
Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline - MSN
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright? - Insider Monkey
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74 - MSN
Heron Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-05-16 - Seeking Alpha
HRTX Stock Price, Quote & Chart | HERON THERAPEUTICS INC (NASDAQ:HRTX) - ChartMill
Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA - MSN
Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan
Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative - Sahm
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Heron Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
H.C. Wainwright cuts Heron Therapeutics stock price target on weak Q1 results - Investing.com
TradingKey - TradingKey
Heron (HRTX) Q1 2026 Earnings Call Transcript - AOL.com
Heron Therapeutics Backs 2026 Rev $173M-$183M >HRTX - Moomoo
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges By GuruFocus - Investing.com Canada
Heron Therapeutics Q1 earnings call highlights - MSN
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility - TipRanks
Heron Therapeutics 1Q Loss/Shr 4c >HRTX - Moomoo
Heron Therapeutics Signals Recovery Despite Soft Q1 - TipRanks
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Heron Therapeutics, Inc. Form 10-Q: Financial Results, Forward-Looking Statements, and Key Risks for Q1 2026 - Minichart
Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Heron Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 - marketscreener.com
Heron Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics (HRTX) reports Q1 loss, lags revenue estimates - MSN
Heron Therapeutics Q1 Earnings Call Highlights - MarketBeat
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline - Yahoo Finance
Heron Therapeutics Reports Q1 2026 Results: 32% Acute Care Revenue Growth, Reaffirms 2026 Guidance - Minichart
HRTX: Q1 sales reached $34.7M, rebounding in March, with strong growth and full-year guidance reaffirmed - TradingView
HRTX: Q1 sales hit $34.7M, acute care up 32% YoY, guidance reaffirmed, and commercial expansion planned - TradingView
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTX - ChartMill
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Heron Therapeutics Q1 2026 earnings preview - MSN
Heron Therapeutics' Q1 revenue falls as oncology sales drop - TradingView
HERON THERAPEUTICS, INC. /DE/ 1Q 2026: Revenue $34.7M, EPS $(0.04) — 10-Q Summary - TradingView
Heron Therapeutics: Q1 Earnings Snapshot - kare11.com
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance - The Manila Times
BRIEF-Heron Therapeutics Q1 EPS USD -0.04 - TradingView
Heron Therapeutics (HRTX) swings to Q1 2026 loss as oncology sales fall and interest costs rise - Stock Titan
[8-K] HERON THERAPEUTICS, INC. /DE/ Reports Material Event - Stock Titan
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Heron Therapeutics Inc-Aktie (HRTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):